Apogee Therapeutics Azioni (NASDAQ: APGE)

Ultime notizie per Apogee Therapeutics (NASDAQ:APGE) Azioni

Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.

Apogee Therapeutics Inc

HC Wainwright &amp; Co. analyst Edward White maintains Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) with a Buy and raises the price target from $21 to $22.

News

Price Target

Analyst Ratings

AURA

HC Wainwright & Co. Maintains Buy on Aura Biosciences, Raises Price Target to $22

The collaboration supports the licensing of part of Curiosity Stream&#39;s content portfolio in China, Hong Kong, and Macau, bringing 56 unique titles, amounting to 148 hours of premium factual content, to audiences across these territories through various platforms. The deal encompasses a diverse range of programming, from short-form documentary series to premium long-form content.

CURI

Curiosity Inks Strategic Distribution Partnership With Off The Fence; Deal Broadens Company's Footprint Across China, Hong Kong, And Macau

Guidance

CVS's Q3 Results Won't Meet Wall Street's Expectations; Plans To Back Away From Current 2024 Guidance

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates DRDGold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRD#NYSE">DRD</a>) with a Buy and maintains $13.25 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on DRDGold, Maintains $13.25 Price Target

Management

CVS Naming Caremark President David Joyner As Its New CEO

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and maintains $1.5 price target.

HC Wainwright & Co. Reiterates Buy on Avino Silver & Gold Mines, Maintains $1.5 Price Target

Biotech

Large Cap

Health Care

General

The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and maintains $8.5 price target.

HC Wainwright & Co. Reiterates Buy on First Majestic Silver, Maintains $8.5 Price Target

The combined companies for the trailing twelve months have generated $235 million in revenue, increasing approximately&nbsp;25%&nbsp;quarter-over-quarter.

BTTR

Better Choice Expects Combined 2025 Pro Forma Basis Revenue And EBITDA To Be Approximately +$270M, And +$10M, Respectively

Better Choice Says Continues To Make Progress Towards Closing Of Its Acquisition Of SRx Health Solutions; Expects Transaction To Close In Late Q4 Of This Year Or Early Q1 Of 2025

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Based on sales trends and order intake in recent years, it expects further market share gains with domestic Chinese OEMs in the coming years.
With the seasonally strong fourth quarter remaining of the year, it reaffirms&nbsp;guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
&nbsp;

Autoliv Now Expects Full Year 2024 Organic Sales Growth To Be 1% Instead Of Previously Expected 2% Due To Unfavorable Market Mix Development

Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.87 billion which beat the analyst consensus estimate of $1.80 billion by 3.78 percent. This is a 0.54 percent increase over sales of $1.86 billion the same period last year.

Earnings

Earnings Beats

Regions Finl Q3 Adj $0.57 Beats $0.53 Estimate, Sales $1.87B Beat $1.80B Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.95 by 5.64 percent. The company reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.53 billion by 0.89 percent. This is a 1.58 percent decrease over sales of $2.60 billion the same period last year.

Earnings Misses

Autoliv Q3 2024 Adj EPS $1.84 Misses $1.95 Estimate, Sales $2.56B Beat $2.53B Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $22 price target.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and lowers the price target from $70 to $60.

Needham Maintains Buy on WNS (Hldgs), Lowers Price Target to $60

Needham analyst Kyle Peterson reiterates Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and maintains $350 price target.

Needham Reiterates Buy on Equifax, Maintains $350 Price Target

Needham analyst Mike Matson downgrades Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Buy to Hold and maintains the price target from $86 to $86.

Downgrades

Needham Downgrades Boston Scientific to Hold, Maintains Price Target to $86

The latest update is out from Apogee Therapeutics, Inc. (APGE). Apogee Therapeutics, Inc. has recently elected Lisa L. Bollinger, M.D., a distingui...

Apogee Therapeutics Welcomes Dr. Bollinger to Board

Analyst Julian Harrison of BTIG maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report), retaining the price target of $81.00...

Buy Rating for Apogee Therapeutics: Promising Prospects for Dupixent and APG808 in COPD Market

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

As we head into the final 90 minutes of the trading session, these are today's top stock gainers: It seems like Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) is ...

Top Stock Gainers Today – LNTH, APGE, and More

Apogee Therapeutics reports Q2 results

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report) today. The company's shares opened t...

Apogee Therapeutics, Inc. (APGE) Receives a Buy from TD Cowen

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Apogee Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apge-stock-quote/">APGE</a>) just reported results for the second quarter of 2024.<ul><li>Apogee Therapeutics reported earnings per share of -60 cents. This met the analyst estimate for EPS of -60 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/apge-stock-earnings-apogee-therapeutics-for-q2-of-2024/">APGE Stock Earnings: Apogee Therapeutics Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

APGE Stock Earnings: Apogee Therapeutics Meets EPS for Q2 2024

Apogee Therapeutics files potential mixed shelf

Franklin Biotechnology Discovery Fund Q2 2024 Commentary

Analyst Julian Harrison of BTIG maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report), with a price target of $81.00. Julia...

Buy Rating on Apogee Therapeutics' APG808: Market Potential and Treatment Advantages Amid FDA Approval Landscape

APGE

APLT

ASND

BNTC

EYPT

GRFS

INSM

LNTH

MIRM

MRNS

MRUS

OCUL

RVNC

SYRE

ZLDPF

Press Releases

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Comments

Apogee Therapeutics

Notizie

Ultime notizie per Apogee Therapeutics (NASDAQ:APGE) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO